Oncothyreon Inc (CASC) Rating Reiterated by Cantor Fitzgerald


's stock had its "hold" rating reissued by equities research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday. They currently have a $2.00 price objective on the biopharmaceutical company's stock.



from Biotech News